fda glp-1 warning news november 2025 Covering Drugs: Employers' Top Questions Answered – Sequoia FDA Drug Recalls and Warnings:

In clinical practice, GLP-1 receptor agonists are used to manage type 2 diabetes and increasingly for weight-loss or metabolic indications

However, any combination protocol should be approached with caution, and our guide on combining multiple peptides covers the principles of safe stacking

Sustained weight loss could make dual GLP-1/GIP receptor agonists more attractive to payers, and increase the affordability of these drugs for healthcare systems

Health economics and outcomes research (HEOR): Evaluate cost-effectiveness, resource utilization, and outcomes compared to other interventions like bariatric surgery

The New England Journal of Medicine , 385(6), 503515

Gratzl, B